Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis
- PMID: 15454785
- DOI: 10.1097/00005537-200410000-00033
Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis
Abstract
Objectives/hypothesis: The aim of the study was the evaluation of the clinical data of 33 patients who had had drooling attributable to various diseases, salivary fistulas, and sialadenitis and had been treated with injection of botulinum toxin type A (Botox). A controlled follow-up study documenting efficiency, possible side effects, and duration of the effect of treatment was also performed.
Study design: Retrospective clinical evaluation.
Methods: Thirty-three patients with drooling attributable to head and neck carcinoma, neurodegenerative diseases, stroke, or idiopathic hypersalivation or with salivary fistula or chronic sialadenitis received injections of 20 to 65 U botulinum toxin type A into salivary glands under sonographic control. The entire salivary flow rate and the output per minute of the salivary analytes thiocyanate, total protein, alpha-amylase, acid phosphatase, kallikrein, and immunoglobulin A were measured at various times before and after injection. The patients were examined with regard to severity of their symptoms, including sonographic control investigation of their cephalic salivary glands.
Results: Twenty-six patients (79% of all patients) reported a distinct improvement of their symptoms after toxin injection. Seven patients noted a return of high salivation rates and requested a second injection after 4 to 7 months. Duration of toxin effect varied widely among individuals. In general, salivary flow rates and thiocyanate output dropped sharply within 1 week after injection and had increased again after a period of 12 to 16 weeks. Conversely, amylase outputs increased during this period, whereas the outputs of the other analytes remained roughly constant. Sonography did not reveal any major changes in salivary gland parenchyma, and side effects were not noted.
Conclusion: Reduction of salivary flow in patients with drooling, salivary fistulas, or chronic sialadenitis by local injection of botulinum toxin type A into the salivary glands proved to be a dependable therapy for these disorders, as shown in the present extended report on 33 patients. Side effects were not observed. The effect of toxin application lasted for approximately 3 months. Based on their results, the authors recommend botulinum toxin injection as the therapy of choice in patients with the problem of drooling.
Similar articles
-
Up-to-date report of botulinum toxin therapy in patients with drooling caused by different etiologies.J Oral Maxillofac Surg. 2003 Apr;61(4):454-7. doi: 10.1053/joms.2003.50086. J Oral Maxillofac Surg. 2003. PMID: 12684962
-
Successful management of drooling with botulinum toxin A in neurologically disabled children.Neuropediatrics. 2002 Dec;33(6):327-30. doi: 10.1055/s-2002-37084. Neuropediatrics. 2002. PMID: 12571790
-
Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands.Laryngoscope. 2002 Jan;112(1):82-6. doi: 10.1097/00005537-200201000-00015. Laryngoscope. 2002. PMID: 11802043
-
Salivary gland application of botulinum toxin for the treatment of sialorrhea.Med Oral Patol Oral Cir Bucal. 2007 Nov 1;12(7):E511-7. Med Oral Patol Oral Cir Bucal. 2007. PMID: 17978775 Review.
-
Botulinum toxin A in the treatment of sialorrhea.Ann Pharmacother. 2007 Jan;41(1):79-85. doi: 10.1345/aph.1H381. Epub 2006 Dec 26. Ann Pharmacother. 2007. PMID: 17190848 Review.
Cited by
-
The therapeutic usage of botulinum toxin (Botox) in non-cosmetic head and neck conditions - An evidence based review.Saudi Pharm J. 2017 Jan;25(1):18-24. doi: 10.1016/j.jsps.2016.04.024. Epub 2016 Apr 30. Saudi Pharm J. 2017. PMID: 28223858 Free PMC article. Review.
-
Modern management of obstructive salivary diseases.Acta Otorhinolaryngol Ital. 2007 Aug;27(4):161-72. Acta Otorhinolaryngol Ital. 2007. PMID: 17957846 Free PMC article. Review.
-
Neurotoxin injection in benign submandibular gland hypertrophy: A first choice treatment.Laryngoscope Investig Otolaryngol. 2020 Feb 17;5(2):217-220. doi: 10.1002/lio2.363. eCollection 2020 Apr. Laryngoscope Investig Otolaryngol. 2020. PMID: 32337352 Free PMC article.
-
Stensen's duct injuries: the role of sialendoscopy and adjuvant botulinum toxin injection.Wideochir Inne Tech Maloinwazyjne. 2013 Jun;8(2):112-6. doi: 10.5114/wiitm.2011.32851. Epub 2013 Jan 21. Wideochir Inne Tech Maloinwazyjne. 2013. PMID: 23837095 Free PMC article.
-
Therapeutic applications of botulinum neurotoxins in head and neck disorders.Saudi Dent J. 2015 Jan;27(1):3-11. doi: 10.1016/j.sdentj.2014.10.001. Epub 2014 Dec 13. Saudi Dent J. 2015. PMID: 25544809 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical